Evaluation of 3-O-Acetyl-11-keto-β-Boswellic Acid (AKBA) to Ameliorate Alzheimer’s Disease Pathology

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that affects the elderly population. Currently, limited treatment options are available for AD, therefore, new adjuvants are required to treat this chronic illness. In this context, bioactive compounds derived from natural sources are promising pharmacological agents. One such compound is 3-O-acetyl-11-keto-β-Boswellic Acid (AKBA) from Boswellia serrata, which has been shown to have neuroprotective effects against okadaic acid-induced AD in a zebrafish model in the current study. AKBA has been shown to have beneficial effects in improving cognition and memory. Additionally, some key genetic markers and proteins have been shown to be modulated by AKBA, thus demonstrating neuroprotective effects.